We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How Much You'd Have If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago
Read MoreHide Full Article
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well.
Another factor that can influence investors is FOMO, or the fear of missing out, especially with tech giants and popular consumer-facing stocks.
What if you'd invested in Catalyst Pharmaceutical (CPRX - Free Report) ten years ago? It may not have been easy to hold on to CPRX for all that time, but if you did, how much would your investment be worth today?
Catalyst Pharmaceutical's Business In-Depth
With that in mind, let's take a look at Catalyst Pharmaceutical's main business drivers.
Coral Gables, FL-based Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company, focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, such as Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy (initially infantile spasms) and Tourette syndrome.
In October 2012, Catalyst in-licensed rights to Firdapse (amifampridine phosphate)from BioMarin Pharmaceutical Inc. to develop and commercialize the product in the United States. Firdapse is currently approved in the European Union as well as in the United States for the symptomatic treatment of LEMS in adults. LEMS is an ultra-rare disease and the company estimates approximately 3,000 LEMS patients in the United States.
The company is also strengthening the commercial portfolio of Firdapse. It already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population. As a result, these patents will now provide intellectual property protection to Firdapse through 2034.
Apart from Firdapse, Catalyst Pharmaceuticals is working on a generic version of Lundbeck’s Sabril (vigabatrin), CPP-109, for the treatment of infantile spasms and complex partial seizures. The company is also looking towards opportunities to diversify its business as well as invest in innovative opportunities for rare diseases.
Catalyst recorded revenues worth $141 million for 2021, reflecting an increase of 18% on a year-over-year basis
Bottom Line
Anyone can invest, but building a successful investment portfolio takes a combination of a few things: research, patience, and a little bit of risk. So, if you had invested in Catalyst Pharmaceutical a decade ago, you're probably feeling pretty good about your investment today.
A $1000 investment made in September 2012 would be worth $10,781.02, or a 978.10% gain, as of September 12, 2022, according to our calculations. Investors should note that this return excludes dividends but includes price increases.
In comparison, the S&P 500 gained 182.86% and the price of gold went up -4.82% over the same time frame.
Looking ahead, analysts are expecting more upside for CPRX.
Catalyst reported optimistic second-quarter results, beating estimates on both counts. Catalyst’s lead drug Firdapse, approved to treat Lambert-Eaton Myasthenic Syndrome — an ultra-rare disease — witnessed an encouraging uptake since its launch in 2019. Analysts are optimistic about this trend and expect the same to continue in 2022. The company’s efforts to develop Firdapse for other rare neuromuscular indications are also impressive. A possible label expansion will boost Catalyst’s top line. Yet, its overdependence on Firdapse for growth and lack of any other promising candidates in its pipeline, are a major concern. However, the company is looking into opportunities to diversify its pipeline. Stiff competition also remains a woe. The stock has underperformed the industry year to date.
Over the past four weeks, shares have rallied 6.26%, and there have been 3 higher earnings estimate revisions in the past two months for fiscal 2022 compared to none lower. The consensus estimate has moved up as well.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's How Much You'd Have If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago
How much a stock's price changes over time is a significant driver for most investors. Not only can price performance impact your portfolio, but it can help you compare investment results across sectors and industries as well.
Another factor that can influence investors is FOMO, or the fear of missing out, especially with tech giants and popular consumer-facing stocks.
What if you'd invested in Catalyst Pharmaceutical (CPRX - Free Report) ten years ago? It may not have been easy to hold on to CPRX for all that time, but if you did, how much would your investment be worth today?
Catalyst Pharmaceutical's Business In-Depth
With that in mind, let's take a look at Catalyst Pharmaceutical's main business drivers.
Coral Gables, FL-based Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company, focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, such as Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy (initially infantile spasms) and Tourette syndrome.
In October 2012, Catalyst in-licensed rights to Firdapse (amifampridine phosphate)from BioMarin Pharmaceutical Inc. to develop and commercialize the product in the United States. Firdapse is currently approved in the European Union as well as in the United States for the symptomatic treatment of LEMS in adults. LEMS is an ultra-rare disease and the company estimates approximately 3,000 LEMS patients in the United States.
The company is also strengthening the commercial portfolio of Firdapse. It already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population. As a result, these patents will now provide intellectual property protection to Firdapse through 2034.
Apart from Firdapse, Catalyst Pharmaceuticals is working on a generic version of Lundbeck’s Sabril (vigabatrin), CPP-109, for the treatment of infantile spasms and complex partial seizures. The company is also looking towards opportunities to diversify its business as well as invest in innovative opportunities for rare diseases.
Catalyst recorded revenues worth $141 million for 2021, reflecting an increase of 18% on a year-over-year basis
Bottom Line
Anyone can invest, but building a successful investment portfolio takes a combination of a few things: research, patience, and a little bit of risk. So, if you had invested in Catalyst Pharmaceutical a decade ago, you're probably feeling pretty good about your investment today.
A $1000 investment made in September 2012 would be worth $10,781.02, or a 978.10% gain, as of September 12, 2022, according to our calculations. Investors should note that this return excludes dividends but includes price increases.
In comparison, the S&P 500 gained 182.86% and the price of gold went up -4.82% over the same time frame.
Looking ahead, analysts are expecting more upside for CPRX.
Catalyst reported optimistic second-quarter results, beating estimates on both counts. Catalyst’s lead drug Firdapse, approved to treat Lambert-Eaton Myasthenic Syndrome — an ultra-rare disease — witnessed an encouraging uptake since its launch in 2019. Analysts are optimistic about this trend and expect the same to continue in 2022. The company’s efforts to develop Firdapse for other rare neuromuscular indications are also impressive. A possible label expansion will boost Catalyst’s top line. Yet, its overdependence on Firdapse for growth and lack of any other promising candidates in its pipeline, are a major concern. However, the company is looking into opportunities to diversify its pipeline. Stiff competition also remains a woe. The stock has underperformed the industry year to date.
Over the past four weeks, shares have rallied 6.26%, and there have been 3 higher earnings estimate revisions in the past two months for fiscal 2022 compared to none lower. The consensus estimate has moved up as well.